[Modification of the FF neuropeptide enhances its hypertensive effect].
Neuropeptide FF (H-Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2) injected intravenously temporarily enhanced the arterial pressure (AP) and the heart rate (HR). However, its role in the regulation of blood circulation is obscure. To study the properties of the molecule, its analogue was synthesized, in which proline in position 7 was substituted with glycine, and leucine in the position 2 with norleucine. Modified neuropeptide FF (FFm) also temporarily and in a dose-dependent manner increased the AP and HR; however, the equal degree of increase was reached at doses of FFm being 5-7 times lesser as compared with the natural peptide. The application of the FFm at hemorrhagic shock excluded mortality of animals during the experiment, considerably increased the degree of AP and HR restoration in the remaining experiments, and improved the survival of animals in 24 hours. It has been found that the level of antibodies to the fragment of hFF1 receptor in the serum is lower in spontaneously hypertensive rats SHR as compared with Wistar rats, but it is increased in patients of cardiological profile as compared with donors. The findings suggest involvement of neuropeptide FF in the regulation of blood circulation; however, the precise mechanisms remain to be determined.
Kapel'ko
V I
VI
Bespalova
Zh D
ZhD
Efremov
E E
EE
Lakomkin
V L
VL
Orlova
Ts R
TsR
Lakomkin
S V
SV
Sidorova
M V
MV
Az'muko
A A
AA
Molokoedov
A S
AS
Sharf
T V
TV
D000818:Animals; D001323:Autoantibodies / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000276:immunology / Q000378:metabolism; D007022:Hypotension / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D009842:Oligopeptides / Q000097:blood / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D018013:Receptors, Neuropeptide / Q000276:immunology / Q000502:physiology; D012771:Shock, Hemorrhagic / Q000503:physiopathology / Q000517:prevention & control*
D001323:Autoantibodies; D009842:Oligopeptides; D010446:Peptide Fragments; D018013:Receptors, Neuropeptide; C083929:neuropeptide FF receptor; C053651:phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide